News
TENX
5.65
+2.91%
0.16
Weekly Report: what happened at TENX last week (1216-1220)?
Weekly Report · 3d ago
Weekly Report: what happened at TENX last week (1209-1213)?
Weekly Report · 12/16 09:38
Weekly Report: what happened at TENX last week (1202-1206)?
Weekly Report · 12/09 09:37
Tenax Therapeutics Appoints Interim CFO Thomas McGauley
TipRanks · 12/04 22:48
Tenax Therapeutics Appoints Thomas A. McGauley As Interim CFO, Effective December 2, 2024
Benzinga · 12/04 22:20
TENAX THERAPEUTICS INC - APPOINTS THOMAS A. MCGAULEY AS INTERIM CFO
Reuters · 12/04 22:17
Weekly Report: what happened at TENX last week (1125-1129)?
Weekly Report · 12/02 09:38
Weekly Report: what happened at TENX last week (1118-1122)?
Weekly Report · 11/25 09:36
Weekly Report: what happened at TENX last week (1111-1115)?
Weekly Report · 11/18 09:35
Roth MKM Sticks to Their Buy Rating for Tenax Therapeutics (TENX)
TipRanks · 11/14 13:13
Tenax Therapeutics, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2024
Press release · 11/13 22:32
Tenax Therapeutics Inc reports results for the quarter - Earnings Summary
Reuters · 11/13 14:16
Tenax Therapeutics GAAP EPS of -$0.19
Seeking Alpha · 11/13 12:28
Tenax Therapeutics Q3 2024 GAAP EPS $(0.19) Beats $(1.39) Estimate, Cash, Cash Equivalents And Investments Of $98.3M, Expected To Provide A Cash Runway Through The End Of 2027
Benzinga · 11/13 12:08
*Tenax Therapeutics: Cash Runway Through End of 2027 >TENX
Dow Jones · 11/13 12:04
*Correct: Tenax Therapeutics 3Q Loss/Shr 19c >TENX
Dow Jones · 11/13 12:03
TENAX THERAPEUTICS INC: CASH RUNWAY THROUGH END OF 2027
Reuters · 11/13 12:00
Press Release: Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Dow Jones · 11/13 12:00
Tenax Therapeutics: Q3 Earnings Snapshot
Barchart · 11/13 06:17
Weekly Report: what happened at TENX last week (1104-1108)?
Weekly Report · 11/11 09:38
More
Webull provides a variety of real-time TENX stock news. You can receive the latest news about Tenax Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).